443 related articles for article (PubMed ID: 7848543)
1. Comparative tolerability profiles of oral antidiabetic agents.
Krentz AJ; Ferner RE; Bailey CJ
Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
[TBL] [Abstract][Full Text] [Related]
2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
3. Antihyperglycaemic agents. Drug interactions of clinical importance.
Scheen AJ; Lefèbvre PJ
Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
Harrower AD
Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
Marchetti P; Giannarelli R; di Carlo A; Navalesi R
Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
[TBL] [Abstract][Full Text] [Related]
6. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus.
Jennings PE
Drugs Aging; 1997 May; 10(5):323-31. PubMed ID: 9143853
[TBL] [Abstract][Full Text] [Related]
7. Oral antidiabetic agents. A guide to selection.
Scheen AJ; Lefèbvre PJ
Drugs; 1998 Feb; 55(2):225-36. PubMed ID: 9506242
[TBL] [Abstract][Full Text] [Related]
8. Management of antidiabetic medications in overdose.
Spiller HA
Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
[TBL] [Abstract][Full Text] [Related]
9. Oral antidiabetic drugs: an overview.
Melander A
Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.
Marchetti P; Navalesi R
Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic relationships of Acarbose.
Salvatore T; Giugliano D
Clin Pharmacokinet; 1996 Feb; 30(2):94-106. PubMed ID: 8906894
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
13. Metformin and the sulphonylureas: the comparative risk.
Campbell IW
Horm Metab Res Suppl; 1985; 15():105-11. PubMed ID: 3935560
[TBL] [Abstract][Full Text] [Related]
14. Comparative tolerability of sulphonylureas in diabetes mellitus.
Harrower AD
Drug Saf; 2000 Apr; 22(4):313-20. PubMed ID: 10789825
[TBL] [Abstract][Full Text] [Related]
15. Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.
Berger W
Horm Metab Res Suppl; 1985; 15():111-5. PubMed ID: 3865878
[TBL] [Abstract][Full Text] [Related]
16. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
[TBL] [Abstract][Full Text] [Related]
17. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Nattrass M; Lauritzen T
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced disorders of glucose metabolism. Mechanisms and management.
Chan JC; Cockram CS; Critchley JA
Drug Saf; 1996 Aug; 15(2):135-57. PubMed ID: 8884164
[TBL] [Abstract][Full Text] [Related]
19. [Pitfalls in treatment with oral antidiabetic agents].
Perusicová J
Vnitr Lek; 1998 Jan; 44(1):30-5. PubMed ID: 9750481
[TBL] [Abstract][Full Text] [Related]
20. Management of non-insulin-dependent diabetes mellitus.
Lefèbvre PJ; Scheen AJ
Drugs; 1992; 44 Suppl 3():29-38. PubMed ID: 1280575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
